-
Sector Analysis
KOL Perspectives: Risankizumab in Crohn’s disease
› This KOL Insight briefing focuses on KOL views of Week 52 Phase II data presented for risankizumab at DDW 2017
-
Sector Analysis
KOL Perspectives: ABT-494 in Crohn’s disease
› This KOL Insight briefing focuses on KOLs views of Phase II ABT-494 data presented at DDW 2017